"Eli Lilly Rises on Obesity Drug Demand, Eyes $1,033 Target"

Eli Lilly CEO on prospect of insurance companies covering weight loss drugsПодробнее

Eli Lilly CEO on prospect of insurance companies covering weight loss drugs

Lilly Pulls Ahead of Novo in Obesity Drug RaceПодробнее

Lilly Pulls Ahead of Novo in Obesity Drug Race

Eli Lilly CEO on obesity drugs, future of companyПодробнее

Eli Lilly CEO on obesity drugs, future of company

Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее

Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan Seigerman

Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet itПодробнее

Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it

People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared HolzПодробнее

People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared HolzПодробнее

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz

Eli Lilly CEO on Fighting Obesity, Developing New DrugsПодробнее

Eli Lilly CEO on Fighting Obesity, Developing New Drugs

Eli Lilly CEO on Fighting Cancer and Obesity, Drug PricingПодробнее

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

Eli Lilly Now Selling Zepbound Vials at 50% DiscountПодробнее

Eli Lilly Now Selling Zepbound Vials at 50% Discount

FDA Approves Eli Lilly’s Zepbound Drug for Weight LossПодробнее

FDA Approves Eli Lilly’s Zepbound Drug for Weight Loss

Eli Lilly Set to Launch Obesity Drug Tirzipatide in India Amidst Weight Loss CrazeПодробнее

Eli Lilly Set to Launch Obesity Drug Tirzipatide in India Amidst Weight Loss Craze

Eli Lilly sells cheaper Zepbound option to meet demand | REUTERSПодробнее

Eli Lilly sells cheaper Zepbound option to meet demand | REUTERS

Eli Lilly Lowers 2024 Revenue Forecast as Weight Loss Drug Demand Slows | WORxK Global NewsПодробнее

Eli Lilly Lowers 2024 Revenue Forecast as Weight Loss Drug Demand Slows | WORxK Global News

Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soarsПодробнее

Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars

Pharmaceutical Company Eli Lilly Caps Out-of-Pocket Cost for Insulin at $35Подробнее

Pharmaceutical Company Eli Lilly Caps Out-of-Pocket Cost for Insulin at $35

Will Eli Lilly’s Weight-Loss Drug Be a Gamechanger? | Vantage with Palki SharmaПодробнее

Will Eli Lilly’s Weight-Loss Drug Be a Gamechanger? | Vantage with Palki Sharma

Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее

Potential for Weight-Loss Drugs Boosts Eli Lilly

Eli Lilly CEO on side effects from weight loss drugsПодробнее

Eli Lilly CEO on side effects from weight loss drugs

Eli Lilly’s Affordable Weight Loss BreakthroughПодробнее

Eli Lilly’s Affordable Weight Loss Breakthrough